30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Welcome and Introductions

Choosing From Multiple Options in Follicular Lymphoma: A Case-Based Panel

Plenary Lecture: Treatment of Patients With Newly Diagnosed DLBCL

What Do I Do for Patients With R/R DLBCL?

Optimizing First-Line Therapy in Patients With CLL

Sequencing Treatment Options in Previously Treated CLL

Polycythemia Vera and Essential Thrombocythemia: Current and Emerging Therapies

Optimal First-Line Treatment and Monitoring in CML

Cases and Conversations: Myeloproliferative Neoplasms

Current and Future Directions in Precision-Based ALL Therapy (Spotlight CE Session)

Key Updates on the Latest Evidence for CAR T and Bispecifics in ALL

Integrating New Data Into Practice: The Evolving Role of T-Cell Therapies in ALL: CAR T-Cell Therapies

Integrating New Data Into Practice: The Evolving Role of T-Cell Therapies in ALL: Bispecific Antibodies

Treatment of Patients With Ph-Positive ALL

Choosing a CAR T-Cell Therapy for Patients With B-ALL

Keynote Lecture: Emerging Role of AI in Hematologic Oncology

Plenary Lecture: Stem Cells in Human Acute Myeloid Leukemia

Smoldering MM: How Much Treatment Does My Patient Need?

Decision-Making and Clinical Applications in NDMM

Hot Seat: Who Will Face the Fire? How the Experts Treat NDMM

From Molecular Insights to Clinical Impact: Translating the Latest Advances in Menin Inhibitors Into Practice (Spotlight CE Session)

Menin Inhibitors in AML: Current Status and Optimal Practical Management

Updates to WHO Criteria for AML and Optimal Diagnostic Workup for AML in 2026

HMA/BCL-2 Inhibition in AML: Overcoming Mechanisms of Resistance

Case-Based Panel Discussion on AML: FLT3 Inhibition

Case-Based Panel Discussion on AML: IDH Inhibition

Plenary Lecture: Curing Myeloma: How Close Are We in 2026?

Sequencing Therapies in a Changing RRMM Landscape